PTLD is a serious, potentially life-threatening complication of solid organ or hematopoietic transplantation, most common in the first year post-transplant when immunosuppression is intense. It represents the most frequent malignancy after solid organ transplantation in many series.

📖 Overview

Heterogeneous group of lymphoid/plasmacytic proliferations ranging from benign polyclonal hyperplasia to aggressive monoclonal lymphoma.
Incidence: ~1–10% overall in solid organ transplant (SOT) recipients; varies by organ, EBV status, age, and immunosuppression intensity.
Higher risk in children/young adults (due to EBV-naïve status) and EBV serodiscordant recipients (D+/R–).

🧬 Aetiology & Pathophysiology

Strongly associated with Epstein-Barr Virus (EBV) reactivation/infection in ~60–90% of cases (especially early PTLD).
Profound immunosuppression → impaired T-cell surveillance → uncontrolled EBV-driven B-cell proliferation.
EBV-negative PTLD more common in late-onset cases (>1–2 years post-transplant), often monomorphic and aggressive.
May involve donor-derived cells in some cases.

📊 Risk Factors & Incidence by Transplant Type

Transplant Type	Approximate Incidence	Notes
Kidney	1–2%	Lowest among common SOT
Liver	1–3%	Often earlier onset
Heart	2–5%	Intermediate risk
Lung	3–10%	Higher due to intense IS
Intestinal / Multivisceral	10–20%	Highest risk
Hematopoietic Cell Transplant (HCT)	1–5%	Often later, more aggressive

Key Risk Factors:

EBV serodiscordance (D+/R–): highest risk, especially pediatric.
Intense immunosuppression (e.g., high-dose calcineurin inhibitors, anti-thymocyte globulin).
Young age / pediatric recipients.
CMV co-infection, certain races (higher in whites), male sex in some series.

🔎 WHO Classification & Forms (2022–2025)

Nondestructive PTLD: Reactive plasmacytic hyperplasia, infectious mononucleosis-like, polymorphic (polyclonal/monoclonal).
Monomorphic PTLD: B-cell (DLBCL most common), T/NK-cell, classic Hodgkin lymphoma-like.
Other: EBV+ mucocutaneous ulcer (localized, indolent).

⚠️ Clinical Presentation

B symptoms: fever, night sweats, unexplained weight loss.
Lymphadenopathy, hepatosplenomegaly, tonsillar enlargement.
Organ involvement: allograft (common in early PTLD), CNS, GI tract, lungs, skin.
May mimic infection, rejection, or malignancy.

Characteristic Appearance Example:

Histopathology of monomorphic PTLD (B-cell type) with EBV-positive cells (Wikipedia / public domain).

CT showing lymphadenopathy in PTLD (example from recent study).

🧪 Investigations & Diagnosis

Gold standard: Tissue biopsy (lymph node or involved organ) with histology, immunohistochemistry (CD20, EBV EBER-ISH), clonality studies.
EBV viral load (quantitative PCR) – monitoring in high-risk patients; elevated in most EBV+ cases.
Imaging: CT/PET-CT for staging and extranodal disease.
Blood tests: LDH, CBC, renal/liver function; bone marrow if systemic.
Follow lymphoma staging protocols (Ann Arbor / Lugano).

💊 Management (Risk-Stratified Sequential Approach, 2025–2026)

Prevention & Monitoring

Pre-transplant EBV serology screening.
Serial EBV PCR monitoring in high-risk (e.g., EBV D+/R–, pediatric, intestinal/lung transplant) – weekly/monthly early post-transplant.
Minimize immunosuppression where possible; no routine antiviral prophylaxis proven effective.

Treatment

First-line (most cases):

Reduction of immunosuppression (RIS): Primary step if graft function allows (reduce calcineurin inhibitors by ~50%, stop antimetabolites) – response in 20–50% of early/polymorphic PTLD.
Rituximab (anti-CD20): 375 mg/m² weekly × 4 (often combined with RIS) – first-line for CD20+ B-cell PTLD; high response in polymorphic/early monomorphic (ORR ~60–90% in low-risk).

Risk-stratified escalation:

Scenario	Recommended Approach	Evidence/Notes
Low-risk (early, localized, polymorphic)	RIS ± rituximab	High response; monitor closely
High-risk / aggressive monomorphic (e.g., DLBCL, extranodal, CNS, high IPI)	Rituximab + chemotherapy (e.g., R-CHOP, DA-EPOCH-R)	Sequential if rituximab alone fails; ORR ~60–70%
Refractory / relapsed	Salvage chemo ± rituximab, radiation, adoptive EBV-CTL (if EBV+), emerging (CAR-T, tabelecleucel, daratumumab)	Poor prognosis; high TRM

Multidisciplinary: transplant specialist, hematologist/oncologist, infectious diseases.
Supportive: infection prophylaxis (PJP, etc.); graft monitoring for rejection.

Prognosis

Variable: early/polymorphic → better with RIS/rituximab; monomorphic/late → poorer (median OS 2–5 years in aggressive cases).
High treatment-related mortality in intensive regimens; recent eras show improving outcomes with risk-adapted strategies.

Exam Tip: In a transplant patient with fever + lymphadenopathy (especially first year), think PTLD! Always prioritize EBV association, biopsy confirmation, and reducing immunosuppression as initial management step.

📚 Key References (2025–2026)

AST Infectious Diseases Community of Practice: PTLD Guidelines (updated 2024).
NCCN B-Cell Lymphomas Guidelines (integrated PTLD, 2025).
UpToDate: Treatment and Prevention of PTLD (Jan 2025).
Polish Lymphoma Research Group: PTLD Recommendations (2025).
Recent studies: Blood (2023–2025), J Clin Oncol (2025 ASCO abstracts), PMC reviews (2025–2026).

This summary provides an evidence-based, concise overview for clinical reference, teaching, or exam preparation.

The content on this website is provided for educational and informational purposes only to support exam preparation (e.g., MLA, MRCP, USMLE) and learning. This is NOT medical advice, diagnosis, treatment, or professional guidance. It does not replace consultation with a qualified healthcare professional, official guidelines (e.g., NICE, GMC, BNF), or supervised clinical practice. Always verify information with current, authoritative sources. Makindo and its contributors accept no liability for any reliance on this content, including errors, omissions, or any resulting harm, loss, or consequences. By using this site, you agree to these terms.

Post-transplant lymphoproliferative disorders (PTLDs)